带状疱疹疫苗接种与加拿大新发痴呆:自然实验分析
该研究利用加拿大安大略省自然实验,比较1946年1月1日前后出生人群(带状疱疹疫苗接种资格阈值)的新发痴呆诊断。跨省比较也支持接种队列痴呆诊断更少。
要点
- 跨省比较显示接种队列痴呆诊断显著少于无接种计划省份同队列。
核心结论
- 自然实验分析提供证据,较标准观察性分析更可能反映因果,带状疱疹疫苗可预防或延迟新发痴呆。
研究设计与样本
- 分析加拿大安大略省自然实验,纳入1930年1月1日至1960年12月31日出生、2016年9月15日在CPCSSN注册的1434名初级保健提供者之一处登记的患者。
- 主要分析比较1946年1月1日前后出生者,次要分析比较1945年1月1日前后出生者,以疫苗资格阈值为断点。
- 痴呆诊断基于1990年1月1日至2022年6月30日电子健康记录;用回归断点分析估计疫苗接种率与痴呆诊断差异。
- 另采用合成双重差分与合成控制法,比较安大略省有资格出生队列与其他省无资格同队列的痴呆发病率趋势。
主要发现
- 项目启动后,安大略省有资格出生队列的新发痴呆诊断显著少于其他无带状疱疹疫苗接种计划的加拿大省份同队列。
临床怎么用
- 对于70岁及以上人群,带状疱疹疫苗接种可能有助于预防或延迟痴呆发生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two natural experiment studies have found evidence that live attenuated herpes zoster vaccination prevents or delays dementia onset. We aimed to determine the effect of live attenuated herpes zoster vaccination on incident dementia diagnoses among people aged 70 years and older using a natural experiment in Ontario, Canada, and to triangulate these findings, using a second natural experiment in Ontario and a quasi-experimental approach that uses data from multiple Canadian provinces. METHODS: Our analysis of natural experiments included people born in Canada between Jan 1, 1930, and Dec 31, 1960, who were registered with one of 1434 primary care providers in the Canadian Primary Care Sentinel Surveillance Network (CPCSSN) on Sept 15, 2016. We compared patients born immediately before versus immediately after Jan 1, 1946, in our primary analysis, and immediately before versus immediately after Jan 1, 1945, in our secondary analysis, as these thresholds determined eligibility for herpes zoster vaccination in Ontario. The key strength of this natural experiment is that these comparison groups are not expected to differ in their health characteristics and behaviours given that all that divides them is a small discrepancy in age. Dementia diagnosis was established using electronic health records data from Jan 1, 1990, to June 30, 2022, from the primary care practices. We used a population-representative survey of people aged 65 years or older in Ontario to measure herpes zoster vaccination uptake. Using regression discontinuity analysis, we estimated the difference in vaccination uptake and dementia diagnoses between individuals born immediately on either side of the eligibility thresholds for herpes zoster vaccination. Additionally, we used synthetic difference-in-differences and a synthetic control method to compare trends in dementia incidence (before versus after the start date of the herpes zoster vaccination programme) among birth cohorts in Ontario who were eligible for vaccination with the same birth cohorts (all of whom were ineligible for vaccination) in other provinces of Canada. FINDINGS: We extracted data on 464 637 patients who were registered with a primary care provider in the CPCSSN as of Sept 15, 2016. Of 232 124 patients born in Ontario included in the analysis, 125 719 (54·2%) were female, 106 354 (45·8%) were male, and 51 (<0·5%) had missing information on sex. Patients born immediately before versus immediately after the two eligibility thresholds for herpes zoster vaccination did not differ in their health characteristics at the time of the start date of the vaccination programme, except for a large difference in their probability of receiving herpes zoster vaccination. Being born immediately before versus immediately after Jan 1, 1946, decreased the probability of receiving a new dementia diagnosis by an absolute difference of 2·0 percentage points (95% CI 0·4-3·5, p=0·012) over a 5·5-year follow-up. Using the Jan 1, 1945, threshold, dementia diagnoses were also reduced by 2·0 percentage points (0·2-3·8, p=0·025) over 5·5 years. After the start of the programme, new dementia diagnoses among the birth cohorts eligible for herpes zoster vaccination in Ontario were significantly less common than in the same birth cohorts in other Canadian provinces that did not have a herpes zoster vaccination programme. INTERPRETATION: This analysis of natural experiments provides evidence, which is more likely to reflect a causal relationship than previous evidence from more standard observational data analyses, that herpes zoster vaccination prevents or delays incident dementia. Mechanistic research into this effect could provide insights into the pathophysiology of dementia and maintenance of neuroimmune health in older age. FUNDING: National Institute on Aging, National Institute of Allergy and Infectious Diseases, Stanford Center for Digital Health, Stanford Knight Initiative for Brain Resilience, Biohub.
引用
- Pomirchy M, Chung S, Bommer C, et al. Herpes zoster vaccination and incident dementia in Canada: an analysis of natural experiments. Lancet Neurol. 2026. PMID: 41579903. doi:10.1016/S1474-4422(25)00455-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。